MarketCapExport financials
Halozyme Therapeutics (HALO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Halozyme Therapeutics Income Statement 2025-2008 | HALO
Brief overview of revenue and earnings at Halozyme Therapeutics
The figures are compared over a five-year interval. Revenue reported by Halozyme Therapeutics was $268 million at the beginning of the period and $1.4 billion at the end. Across the full period, sales moved by +421.9%; the average annual rate was 39.2%. The annual growth rate indicates an exceptionally strong top-line trend.
The gross result shifted from $224 million to $1.2 billion, or +420.8%. Costs absorbed a larger share of revenue over the period. Gross profit as a share of revenue changed from 83.8% to 83.6%. The economics of the core business remained steady.
EBITDA was $148 million at the beginning and $480 million at the end of the period (+225.6%). The operating result developed less favorably than sales. The EBITDA share of revenue changed from 55.1% to 34.4%. Cost pressure reduced operating profitability.
The net result moved from 129 million dollars to 317 million dollars, or +145.5%. Net earnings remained broadly steady over the period.
The five-year change in capitalization reached +56.7%: from $6.2 billion to $9.7 billion. Investors responded cautiously to the improvement in the business.
Summary assessment
The financial profile remains mixed, with strengths and risks moving in different directions. The financial profile benefits from steady gross profitability, a stronger final result and a larger revenue base. The weaker side of the profile includes a declining EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
9.66 B | 7.34 B | 4.75 B | 6.84 B | 4.99 B | 6.16 B | 2.8 B | 2.3 B | 2.62 B | 1.44 B | 1.11 B | 1.75 B | 1.8 B | 788 M | 1.09 B | 713 M | - | - |
Shares |
120 M | 127 M | 132 M | 137 M | 141 M | 136 M | 144 M | 144 M | 136 M | 128 M | 127 M | 123 M | 113 M | 111 M | 103 M | 101 M | - | - |
Historical Prices |
80.6 | 57.9 | 36 | 50 | 35.5 | 45.2 | 19.6 | 17.2 | 19.7 | 12.8 | 8.13 | 15.1 | 14.1 | 5.45 | 11.5 | 7.09 | 7.23 | 5.17 |
Net Income |
317 M | 444 M | 282 M | 202 M | 403 M | 129 M | -72.2 M | -80.3 M | 63 M | -103 M | -32.2 M | -68.4 M | -83.5 M | -53.6 M | -19.8 M | -53.2 M | -58.4 M | - |
Revenue |
1.4 B | 1.02 B | 829 M | 660 M | 443 M | 268 M | 196 M | 152 M | 317 M | 147 M | 135 M | 75.3 M | 54.8 M | 42.3 M | 56.1 M | 13.6 M | 13.7 M | - |
Cost of Revenue |
229 M | 159 M | 192 M | 139 M | 81.4 M | 43.4 M | 45.5 M | 10.1 M | 31.2 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 150 M | 142 M | 285 M | 113 M | 106 M | 52.6 M | 48.6 M | 41.2 M | 55.8 M | - | - | - |
Operating Income |
469 M | 551 M | 338 M | 268 M | 276 M | 144 M | -67.6 M | -69.3 M | 81 M | -83.2 M | -27.5 M | -63 M | -80.4 M | -53.6 M | -19.8 M | -54.3 M | -58.5 M | - |
Interest Expense |
21.5 M | 23.8 M | 18.8 M | 16.9 M | 7.53 M | 20.4 M | 11.6 M | 18 M | 22 M | 20 M | 5.2 M | 5.58 M | 3.27 M | - | - | 1.02 M | 97.7 K | - |
EBITDA |
480 M | 562 M | 349 M | 274 M | 279 M | 148 M | -63.5 M | -66.9 M | 83.2 M | -80.8 M | -25.8 M | -61.3 M | -79.2 M | -52.5 M | -18.7 M | -52.7 M | -57 M | - |
Operating Expenses |
- | - | - | - | - | - | 218 M | 211 M | 204 M | 197 M | 133 M | 116 M | 129 M | 94.9 M | 75.7 M | - | - | - |
General and Administrative Expenses |
207 M | 154 M | 149 M | 144 M | 50.3 M | 45.7 M | 77.3 M | 60.8 M | 53.8 M | 45.9 M | 40 M | 35.9 M | 32.3 M | 24.8 M | 18.1 M | 15.1 M | 15.2 M | - |
All numbers in USD currency
Quarterly Income Statement Halozyme Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
117 M | 118 M | 117 M | 121 M | 123 M | 123 M | 127 M | 127 M | 127 M | 127 M | 132 M | 132 M | 135 M | 135 M | 137 M | 138 M | 138 M | 138 M | 142 M | 142 M | 138 M | 135 M | 137 M | 136 M | 137 M | 141 M | 146 M | 145 M | 145 M | 144 M | 144 M | 144 M | 143 M | 142 M | 141 M | 134 M | 129 M | 127 M | 128 M | 128 M | 128 M | 127 M | 127 M | 126 M | 125 M | 124 M | 124 M | 124 M | 119 M | 114 M | 113 M | 112 M | 112 M | 112 M | 112 M | 112 M | 108 M | 103 M | 103 M | 103 M | 101 M |
Net Income |
230 M | 150 M | 175 M | 165 M | 118 M | - | 137 M | 93.2 M | 76.8 M | - | 81.8 M | 74.8 M | 39.6 M | - | 61.6 M | 22.7 M | 60.1 M | - | 217 M | 91.5 M | 27.9 M | 73.2 M | 36.2 M | 25.8 M | -6.1 M | -34.4 M | -25 M | -14.6 M | 1.8 M | -2.13 M | -27.8 M | -22.9 M | -27.5 M | 124 M | 2.75 M | -30.8 M | -32.9 M | -27.4 M | -28.9 M | -26.9 M | -19.8 M | -27.4 M | -28.9 M | -26.9 M | -19.8 M | -5.27 M | -20.3 M | -16.3 M | -26.5 M | -22 M | -19.3 M | -22.9 M | -19.3 M | -4.41 M | -20 M | -14 M | -15.1 M | -18.4 M | 5.17 M | 3.12 M | -9.64 M |
Revenue |
481 M | 377 M | 354 M | 326 M | 265 M | - | 290 M | 231 M | 196 M | - | 216 M | 221 M | 162 M | - | 209 M | 152 M | 117 M | - | 116 M | 136 M | 89 M | 122 M | 65.3 M | 55.2 M | 25.4 M | 53.7 M | 46.2 M | 39.1 M | 56.9 M | 60.2 M | 25.6 M | 35.2 M | 30.9 M | 190 M | 63.7 M | 33.8 M | 29.6 M | 39 M | 31.9 M | 33.3 M | 42.5 M | 39 M | 20.8 M | 43.4 M | 18.7 M | 30.4 M | 14.6 M | 18.4 M | 12 M | 12.5 M | 16 M | 14.5 M | 11.8 M | 21.8 M | 5.33 M | 7.76 M | 7.44 M | 2.41 M | 22.9 M | 23.2 M | 7.54 M |
Cost of Revenue |
79.2 M | 79.2 M | 55.2 M | 46.4 M | 48.4 M | - | 49.4 M | 39.6 M | 28.3 M | - | 54.8 M | 50.1 M | 35.2 M | - | 47.3 M | 33.9 M | 15.9 M | - | 18.6 M | 23 M | 18.2 M | - | 5.57 M | 5.74 M | 5.79 M | - | 22.3 M | 1.88 M | 4.65 M | - | 626 K | 836 K | 3.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.18 M | 3.48 M | 597 K | 2.36 M | 6.01 M | 6.87 M | 3.88 M | 3.74 M | 5.06 M | 5.64 M | 3.65 M | 3.75 M | 5.1 M | 5.26 M | 4.99 M | 3.89 M | 5.42 M | 4.2 M | 5.39 M | 5.18 M | 5.42 M | 4.2 M | 5.39 M | 5.18 M | 4 M | 4.48 M | 3.57 M | 3.05 M | 6.27 M | 9.34 M | 1.82 M | 769 K | 806 K | 489 K | 382 K | 117 K | - | - | - | - |
Operating Income |
288 M | 185 M | 218 M | 202 M | 142 M | - | 163 M | 117 M | 95.5 M | - | 88.3 M | 94.5 M | 53.8 M | - | 83.3 M | 34.1 M | 75.7 M | - | 75.6 M | 93 M | 50.7 M | - | 40.3 M | 29.6 M | -3.22 M | - | -24.5 M | -14 M | 2.97 M | - | -25.5 M | -20.1 M | -23.7 M | - | 8.08 M | -25.5 M | -27.5 M | - | -22.7 M | -21.7 M | -16.2 M | - | -23.2 M | 4.23 M | -13.9 M | - | -19 M | -14.9 M | -25.2 M | - | -18.5 M | -22.1 M | -18.5 M | - | -20 M | -14 M | -15.1 M | - | 5.15 M | 3.1 M | -9.66 M |
Interest Expense |
2.84 M | 1.32 M | 5.33 M | 6.89 M | 6.82 M | - | 6.47 M | 5.03 M | 4.99 M | - | 4.79 M | 3.19 M | 4.54 M | - | 7.51 M | 3.1 M | 1.76 M | - | 1.75 M | 1.75 M | 1.96 M | - | 4.99 M | 5 M | 5.35 M | - | 2.08 M | 2.61 M | 3.2 M | - | 4.29 M | 4.77 M | 5.23 M | - | 5.54 M | 5.54 M | 5.45 M | - | 5.25 M | 5.25 M | 3.88 M | - | 1.3 M | 1.3 M | 1.3 M | - | 1.38 M | 1.45 M | 1.38 M | - | 850 K | 849 K | 848 K | - | - | - | - | - | 12.4 K | 20.4 K | 23.9 K |
EBITDA |
292 M | 189 M | 221 M | 205 M | 144 M | - | 166 M | 120 M | 98 M | - | 91 M | 97.3 M | 56.4 M | - | 85.3 M | 35.2 M | 76.4 M | - | 76.3 M | 93.8 M | 51.5 M | - | 41.1 M | 30.4 M | -2.37 M | - | -23.5 M | -13 M | 3.96 M | - | -24.9 M | -19.5 M | -23.1 M | - | 8.58 M | -24.9 M | -26.9 M | - | -22 M | -21.1 M | -15.7 M | - | -22 M | 5.05 M | -13.5 M | - | -17.7 M | -14.1 M | -24.8 M | - | -17.6 M | -21.5 M | -18.2 M | - | -19.2 M | -13.5 M | -14.9 M | - | 6 M | 3.71 M | -9.33 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.1 M | 25 M | 25.7 M | 28.6 M | 85.7 M | 70.8 M | 53.1 M | 54 M | 60.3 M | 51 M | 55.3 M | 54.6 M | 63.6 M | 55.7 M | 59.2 M | 57.1 M | 61.6 M | 54.6 M | 55.1 M | 58.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
57 M | 57.9 M | 46.1 M | 41.6 M | 42.4 M | - | 41.2 M | 35.7 M | 35.1 M | - | 35.3 M | 38.9 M | 37.4 M | - | 34.5 M | 57.5 M | 13.8 M | - | 13.2 M | 12.3 M | 11.1 M | - | 11.7 M | 11 M | 12.6 M | - | 18 M | 17.3 M | 18 M | - | 14.9 M | 14.4 M | 13.6 M | - | 13.3 M | 13.1 M | 12.6 M | - | 11.6 M | 11.2 M | 10.8 M | - | 10.2 M | 9.81 M | 9.4 M | - | 8.59 M | 8.75 M | 10.2 M | - | 8.14 M | 7.3 M | 7.56 M | - | 5.63 M | 5.58 M | 6.62 M | - | 4.26 M | 4.57 M | 3.41 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Halozyme Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Germany
Israel
Britain
Canada
Russia
Schweiz
China